|Bid||85.50 x 700|
|Ask||85.51 x 200|
|Day's Range||85.30 - 86.14|
|52 Week Range||66.93 - 86.90|
|PE Ratio (TTM)||32.07|
|Dividend & Yield||2.72 (3.15%)|
|1y Target Est||N/A|
A look under the hood at AbbVie Inc., how Novartis is prepping to fight Regeneron, and can Clovis capture the lead in the PARP race?
Novartis's generics unit Sandoz said the European Commission approved Erelzi, its biosimilar to Amgen's Enbrel, to treat inflammatory diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis. The approval was based on a development programme that demonstrated that Erelzi, a biosimilar of the drug also known as etanercept, matches its reference medicine in terms of safety, efficacy, and quality, Sandoz said in a statement on Tuesday.
The Zacks Analyst Blog Highlights: Novartis, Roche, Shire, Neos and Novo Nordisk